Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Haddon, D James ^a   Diep, Vivian K ^a   Price, Jordan V ^b   Limb, Cindy ^a   Utz, Paul J ^a   Balboni, Imelda ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN AUTOANTIGEN; AUTOANTIBODY; AUTOANTIGEN; B CELL ACTIVATING FACTOR ANTIBODY; COLLAGEN IV AUTOANTIGEN; COLLAGEN X AUTOANTIGEN; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; FIBRIN ANTIBODY; HEMOGLOBIN; HISTONE H1 AUTOANTIGEN; HISTONE H2A AUTOANTIGEN; HISTONE H2B AUTOANTIGEN; HISTONE H4 AUTOANTIGEN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOANTIGEN MICROARRAY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY BIOPSY; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; MALE; PROLIFERATIVE NEPHRITIS; PROTEIN MICROARRAY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE LEVEL; BLOOD; DNA MICROARRAY; GENETICS; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PROCEDURES;

ADOLESCENT; AUTOANTIBODIES; AUTOANTIGENS; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84935504088     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0682-6     Document Type: Article

References (52)

1. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33.
2. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004;34:501-37.
3. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990;33:634-43.
4. Ehrenstein MR, Katz DR, Griffiths MH, Papadaki L, Winkler TH, Kalden JR, et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 1995;48:705-11.
5. Mina R, Brunner HI. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am. 2010;36:53-80. vii-viii.
6. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58:556-62.
7. Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17:314-22.
8. Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, et al. Longterm followup of childhood lupus nephritis. J Rheumatol. 2002;29:2635-42.
9. Bennett M, Brunner HI. Biomarkers and updates on pediatrics lupus nephritis. Rheum Dis Clin North Am. 2013;39:833-53.
10. Gilliam BE, Ombrello AK, Burlingame RW, Pepmueller PH, Moore TL. Measurement of autoantibodies in pediatric-onset systemic lupus erythematosus and their relationship with disease-associated manifestations. Semin Arthritis Rheum. 2012;41:840-8.
11. Marks SD, Williams SJ, Tullus K, Sebire NJ. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transplant. 2008;23:3521-6.
12. Chan RW, Tam LS, Li EK, Lai FM, Chow KM, Lai KB, et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 2003;48:1326-31.
13. Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther. 2008;10:R112.
14. Suzuki M, Ross GF, Wiers K, Nelson S, Bennett M, Passo MH, et al. Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol. 2007;22:2047-57.
15. Brunner HI, Bennett MR, Mina R, Suzuki M, Petri M, Kiani AN, et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 2012;64:2687-97.
16. Rovin BH, Birmingham DJ, Nagaraja HN, Yu CY, Hebert LA. Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis. 2007;65:187-93.
17. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol. 2000;76:227-324.
18. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med. 2002;8:295-301.
19. Balboni I, Niewold TB, Morgan G, Limb C, Eloranta ML, Rönnblom L, et al. Interferon-aα induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum. 2013;65:2424-9.
20. Price JV, Haddon DJ, Kemmer D, Delepine G, Mandelbaum G, Jarrell JA, et al. Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J Clin Invest. 2013;123:5135-45.
21. Price JV, Tangsombatvisit S, Xu G, Yu J, Levy D, Baechler EC, et al. On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nat Med. 2012;18:1434-40.
22. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100:2610-5.
23. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009;60:3098-107.
24. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197:711-23.
25. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3, e491.
26. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
27. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241-50.
28. Balboni I, Chan SM, Kattah M, Tenenbaum JD, Butte AJ, Utz PJ. Multiplexed protein array platforms for analysis of autoimmune diseases. Annu Rev Immunol. 2006;24:391-418.
29. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207-10.
30. Autoantigen microarray data series on GEO. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69662.
31. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-21.
32. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013.
33. Tibshirani R, Chu G, Narasimhan B, Li J. samr: SAM: significance analysis of microarrays. 20th ed. Stanford: R package; 2011.
34. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, et al. gplots: various R programming tools for plotting data. 3th ed. R package: New Milford; 2013.
35. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B. 1996;267-288.
36. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1-22.
37. Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Frémeaux-Bacchi V, et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant. 2006;21:3115-21.
38. Mahler M, van Schaarenburg RA, Trouw LA. Anti-C1q autoantibodies, novel tests, and clinical consequences. Front Immunol. 2013;4:117.
39. Renaudineau Y, Croquefer S, Jousse S, Renaudineau E, Devauchelle V, Guéguen P, et al. Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum. 2006;54:2523-32.
40. McIntosh RM, Kaufman DB, Griswold W, Smith FG, Vernier RL. Glomerular localization of ibrinogen-clinicopathologic, prognostic and therapeutic considerations. J Chronic Dis. 1971;24:787-800.
41. Nagayama Y, Imura H, Muso R. Decrease in renal function following decreased fibrinogen and raised fibrin degradation products in lupus nephritis with nephrotic syndrome. Scand J Urol Nephrol. 1992;26:387-91.
42. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-31.
43. Li PH, Wong WH, Lee TL, Lau CS, Chan TM, Leung AM, et al. Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese. Rheumatology (Oxford). 2013;52:337-45.
44. Hoffman IE, Peene I, Meheus L, Huizinga TW, Cebecauer L, Isenberg D, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis. 2004;63:1155-8.
45. Jurencák R, Fritzler M, Tyrrell P, Hiraki L, Benseler S, Silverman E. Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis, and clinical correlations. J Rheumatol. 2009;36:416-21.
46. Levy DM, Peschken CA, Tucker LB, Chédeville G, Huber AM, Pope JE, et al. Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort. Arthritis Care Res (Hoboken). 2013;65:152-60.
47. Ravelli A, Wisnieski JJ, Ramenghi B, Ballardini G, Zonta L, Martini A. IgG autoantibodies to complement C1q in pediatric-onset systemic lupus erythematosus. Clin Exp Rheumatol. 1997;15:215-9.
48. Kozyro I, Perahud I, Sadallah S, Sukalo A, Titov L, Schifferli J, et al. Clinical value of autoantibodies against C1q in children with glomerulonephritis. Pediatrics. 2006;117:1663-8.
49. Wu FQ, Zhao Q, Cui XD, Zhang W. C1q and anti-C1q antibody levels are correlated with disease severity in Chinese pediatric systemic lupus erythematosus. Rheumatol Int. 2011;31:501-5.
50. Vynios DH, Tsagaraki I, Grigoreas GH, Samiotaki M, Panayotou G, Kyriakopoulou D, et al. Autoantibodies against aggrecan in systemic rheumatic diseases. Biochimie. 2006;88:767-73.
51. Li QZ, Zhen QL, Xie C, Wu T, Mackay M, Aranow C, et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest. 2005;115:3428-39.
52. Quintana FJ, Getz G, Hed G, Domany E, Cohen IR. Cluster analysis of human autoantibody reactivities in health and in type 1 diabetes mellitus: a bio-informatic approach to immune complexity. J Autoimmun. 2003;21:65-75.